Diskussionsleiter: K. Kelemen (Heidelberg), C. Meyer (Düsseldorf), C. A. Perings (Lünen)
| (P369) | Intraoperative ablation for paroxysmal, persistent and permanent atrial fibrillation: a loop-recorder based follow up. |
| R. Ö. Akbulak, F. Hartel, S. Pecha, A. Aydin, A. Sultan, J. Lüker, B. A. Hoffmann, N. Gosau, H. Servatius, F. Wagner, S. Willems, D. Steven (Hamburg) | |
| (P370) | Predictors for pacemaker implantation after concomitant surgical ablation for atrial fibrillation (AF) |
| S. Pecha, T. Schäfer, T. Ahmadzade, H. Reichenspurner, F. Wagner (Hamburg) | |
| (P371) | Underlying mechanisms of life threatening interactions of a combination therapy with dronedarone and digitalis |
| G. Frommeyer, J. Schulze Grotthoff, L. Eckardt, P. Milberg (Münster) | |
| (P372) | Antiarrhythmic effect of Vernakalant due to reduction of dispersion of repolarization and suppression of early afterdepolarizations in a rabbit model of acquired long-QT-syndrome |
| P. Milberg, G. Frommeyer, C. Clauß, L. Eckardt (Münster) | |
| (P373) | Which patients are most suitable for dronedarone? Analysis from the MADRE-study. |
| S. Said, H.-D. Esperer, K. Kluba, C. Genz, T. Rauwolf, H. Bönigk, J. Herold, A. Schmeißer, R. Braun-Dullaeus (Magdeburg) | |
| (P374) | Effectiveness of antiarrhythmic drug therapy in the early period after pulmonary vein isolation for treatment of symptomatic atrial fibrillation |
| C. Sohns, V. von Gruben, S. T. Sossalla, J. Seegers, L. Lüthje, D. Vollmann, M. Zabel (Göttingen) | |
| (P375) | Surgical atrial fibrillation ablation in patients with longstanding persistent AF - insights from continously monitored patients |
| T. Hanke, E. Charitos, M. Baldewig, U. Stierle, S. Mohamed, H.-H. Sievers (Lübeck) | |
| (P376) | Pulmonary vein reconnection after antral linear catheter ablation of paroxysmal and persistent atrial fibrillation |
| K. Wasmer, J. Köbe, D. Dechering, A. Bittner, S. Zellerhoff, C. Pott, G. Frommeyer, B. Rath, P. Milberg, G. Mönnig, L. Eckardt (Münster; Santiago, CL) | |
| (P377) | Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial |
| G. Breithardt, S. R. Stevens, Y. Lokhnygina, M. Patel, D. Singer, J. Halperin, G. Hankey, W. Hacke, R. C. Becker, C. C. Nessel, K. Mahaffey, K. Fox, R. Califf, J. P. Piccini (Münster, Heidelberg; Durham, Boston, New York, Raritan, US; Perth, AU; Edinburgh, UK) | |
| (P378) | SAFE-AF : Safety of Fondaparinux in electric cardioversion of atrial fibrillation |
| H. Omran, C. Stellbrink, T. Faber, J.-Y. Le-Heuzey, E. M. Aliot, S. Kropff, N. Banik, A. Cohen (Bonn, Bielefeld, Freiburg im Breisgau, München; Paris, Nancy, FR) | |
| (P379) | Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial |
| C. Bode, J. Halperin, A. Hellkamp, Y. Lokhnygina, M. Patel, R. C. Becker, G. Breithardt, W. Hacke, G. Hankey, C. C. Nessel, D. Singer, S. Berkowitz, R. Califf, K. Fox, K. Mahaffey (Freiburg im Breisgau, Münster, Heidelberg; New York, Durham, Raritan, Boston, Montville, US; Perth, AU; Edinburgh, UK) |